ATE374827T1 - Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1 - Google Patents

Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1

Info

Publication number: ATE374827T1
Authority: AT; Austria
Prior art keywords: protein; interest; cyclin; overexpression; nucleic acid
Prior art date: 1998-08-11

Application number

AT99942098T

Other languages

English (en)

Inventor

Shaw-Fen Hu

Jean Gudas

David Brankow

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-11

Filing date

1999-08-11

Publication date

2007-10-15

1999-08-11 Application filed by Amgen Inc filed Critical Amgen Inc

2007-10-15 Application granted granted Critical

2007-10-15 Publication of ATE374827T1 publication Critical patent/ATE374827T1/de

Links

108090000623 proteins and genes Proteins 0.000 title abstract 9
102000004169 proteins and genes Human genes 0.000 title abstract 9
230000002018 overexpression Effects 0.000 title 2
102000016736 Cyclin Human genes 0.000 title 1
108050006400 Cyclin Proteins 0.000 title 1
108090000259 Cyclin D Proteins 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 4
108020004707 nucleic acids Proteins 0.000 abstract 4
150000007523 nucleic acids Chemical class 0.000 abstract 4
210000004027 cell Anatomy 0.000 abstract 3
108010019673 Darbepoetin alfa Proteins 0.000 abstract 2
108090000394 Erythropoietin Proteins 0.000 abstract 2
102000003951 Erythropoietin Human genes 0.000 abstract 2
102000008108 Osteoprotegerin Human genes 0.000 abstract 2
108010035042 Osteoprotegerin Proteins 0.000 abstract 2
229940105423 erythropoietin Drugs 0.000 abstract 2
210000003527 eukaryotic cell Anatomy 0.000 abstract 2
229940039781 leptin Drugs 0.000 abstract 2
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 abstract 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
102000016267 Leptin Human genes 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
-1 OPG-Fc Chemical compound 0.000 abstract 1
210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
238000012258 culturing Methods 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT99942098T 1998-08-11 1999-08-11 Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1 ATE374827T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9608698P	1998-08-11	1998-08-11
US09/371,309 US6210924B1 (en)	1998-08-11	1999-08-10	Overexpressing cyclin D 1 in a eukaryotic cell line

Publications (1)

Publication Number	Publication Date
ATE374827T1 true ATE374827T1 (de)	2007-10-15

Family

ID=22255220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99942098T ATE374827T1 (de)	1998-08-11	1999-08-11	Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1

Country Status (15)

Country	Link
US (1)	US6210924B1 (de)
EP (1)	EP1105507B1 (de)
JP (1)	JP4562915B2 (de)
KR (1)	KR100502701B1 (de)
CN (1)	CN1151263C (de)
AT (1)	ATE374827T1 (de)
AU (1)	AU747640B2 (de)
CA (1)	CA2338820C (de)
CY (1)	CY1106987T1 (de)
DE (1)	DE69937243T2 (de)
DK (1)	DK1105507T3 (de)
ES (1)	ES2291038T3 (de)
HU (1)	HU230247B1 (de)
PT (1)	PT1105507E (de)
WO (1)	WO2000009714A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020090646A1 (en) *	2000-05-03	2002-07-11	Amgen Inc.	Calcitonin-related molecules
EP2295081B1 (de)	2001-06-26	2018-10-31	Amgen Inc.	Antikörper gegen OPGL
WO2003002187A2 (en) *	2001-06-26	2003-01-09	Photomed Technologies, Inc.	Multiple wavelength illuminator
KR100427299B1 (ko) *	2001-08-10	2004-04-14	한국생명공학연구원	인체 골 재흡수 억제인자（ｈＯＰＧ）를 생산하는 재조합플라스미드 ｐＧＨＯＰＧ（ＫＣＴＣ１０１９ＢＰ）
US7718776B2 (en)	2002-04-05	2010-05-18	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
KR101317045B1 (ko)	2002-09-06	2013-10-16	암젠 인코포레이티드	치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1739179A1 (de) *	2005-06-30	2007-01-03	Octapharma AG	Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
EP2500416A1 (de)	2006-09-13	2012-09-19	Abbott Laboratories	Verbesserungen an Zellkulturen
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
TW201307390A (zh) *	2007-02-02	2013-02-16	Amgen Inc	海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US7982016B2 (en)	2007-09-10	2011-07-19	Amgen Inc.	Antigen binding proteins capable of binding thymic stromal lymphopoietin
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX340971B (es)	2009-11-23	2016-08-02	Amgen Inc *	Fragmento cristalizable (fc) de anticuerpo monomerico.
PL2591121T3 (pl) *	2010-07-05	2018-07-31	Lonza Ltd	Linia komórek produkcyjnych
MX2013008833A (es)	2011-02-02	2013-12-06	Amgen Inc	Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
US9441039B2 (en)	2012-05-07	2016-09-13	Amgen Inc.	Anti-erythropoietin antibodies
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
EP3041863A4 (de)	2013-09-05	2017-08-16	Amgen Inc.	Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
US10435464B1 (en)	2014-09-05	2019-10-08	Coherus Biosciences, Inc.	Methods for making recombinant proteins
WO2016044224A1 (en)	2014-09-15	2016-03-24	Amgen Inc.	Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
MX377591B (es)	2014-10-15	2025-03-10	Amgen Inc	Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
CN111018987B (zh)	2014-12-05	2023-11-21	鸿运华宁（杭州）生物医药有限公司	一种能与人内皮素受体特异性结合的抗体及其应用
EP3356415B1 (de)	2015-09-29	2024-05-01	Amgen Inc.	Asgr-inhibitoren
US11261462B2 (en)	2016-01-27	2022-03-01	Just-Evotec Biologics, Inc.	Inducible expression from transposon-based vectors and uses
US11098310B2 (en)	2016-01-27	2021-08-24	Just-Evotec Biologics, Inc.	Expression from transposon-based vectors and uses
JP6937309B2 (ja)	2016-01-27	2021-09-22	ジャスト−エヴォテックバイオロジックス、インコーポレイテッド	ハイブリッドプロモーターおよびその使用
TWI826351B (zh)	2016-05-31	2023-12-21	大陸商鴻運華寧（杭州）生物醫藥有限公司	Ｒ抗體,其藥物組合物及其應用
WO2018144784A1 (en)	2017-02-01	2018-08-09	Smet Pharmaceutical Inc.	MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
CN117126279A (zh)	2018-03-20	2023-11-28	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN110357959B (zh)	2018-04-10	2023-02-28	鸿运华宁（杭州）生物医药有限公司	Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
IL307155B2 (en)	2018-05-01	2025-11-01	Amgen Inc	Antibodies with modulated glycan profiles
CN110655577A (zh)	2018-06-13	2020-01-07	鸿运华宁（杭州）生物医药有限公司	APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
MA56110A (fr)	2019-06-07	2022-04-13	Amgen Inc	Constructions de liaison bispécifiques à lieurs clivables de manière sélective
CN112239507A (zh)	2019-07-17	2021-01-19	鸿运华宁（杭州）生物医药有限公司	ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP4161969A1 (de)	2020-06-04	2023-04-12	Amgen Inc.	Bispezifische bindungskonstrukte
US20250277024A1 (en)	2020-12-03	2025-09-04	Amgen Inc.	Molecules with multiple binding domains
CN115141276A (zh)	2021-03-31	2022-10-04	鸿运华宁（杭州）生物医药有限公司	一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
JP2024520666A (ja)	2021-06-04	2024-05-24	アムジェンリサーチ（ミュニック）ゲゼルシャフトミットベシュレンクテルハフツング	Ｔ細胞エンゲージャ分子及びその使用
CN113698466B (zh) *	2021-07-30	2023-07-14	山东农业大学	Ccnd1在制备禽反转录病毒生产增强剂中的应用
CN119744271A (zh)	2022-09-08	2025-04-01	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
AU2023367846A1 (en)	2022-10-26	2025-05-01	Amgen Inc.	Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
WO2025259749A1 (en)	2024-06-12	2025-12-18	Amgen Inc.	Stable single-chain variable fragments
WO2026072755A2 (en)	2024-09-26	2026-04-02	Amgen Inc.	Single-chain fab proteins and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
IL79176A (en)	1985-06-20	1992-06-21	Kirin Amgen Inc	Process for the recovery of erythropoietin from a fluid
US5013718A (en)	1986-11-21	1991-05-07	Amgen, Inc.	Method for treating iron overload using EPO
KR100221066B1 (ko)	1989-10-13	1999-10-01	스튜어트 엘.왓트	에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
JPH06117187A (ja)	1992-10-08	1994-04-26	Iseki Tory Tech Inc	シールド掘削機
US5514571A (en)	1993-08-05	1996-05-07	University Technologies International Inc.	Cyclin D1 negative regulatory activity
US5521066A (en)	1993-09-13	1996-05-28	Bristol-Myers Squibb Company	Periplasmic membrane-bound system for detecting protein-protein interactions
CA2179014C (en)	1993-12-17	2003-07-29	Spinal Cord Society	Method for inducing dna synthesis in neurons
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU6028396A (en)	1995-06-07	1996-12-30	Amgen, Inc.	Ob protein compositions and method
ATE259650T1 (de)	1995-08-17	2004-03-15	Amgen Inc	Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
PT866720E (pt)	1995-11-22	2004-06-30	Amgen Inc	Proteina ob para aumentar a massa do tecido mole
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
GB9608143D0 (en) *	1996-04-19	1996-06-26	Ver Nl Kanker Inst	Assay

1999
- 1999-08-10 US US09/371,309 patent/US6210924B1/en not_active Expired - Lifetime
- 1999-08-11 KR KR10-2001-7001843A patent/KR100502701B1/ko not_active Expired - Lifetime
- 1999-08-11 PT PT99942098T patent/PT1105507E/pt unknown
- 1999-08-11 EP EP99942098A patent/EP1105507B1/de not_active Expired - Lifetime
- 1999-08-11 WO PCT/US1999/018213 patent/WO2000009714A1/en not_active Ceased
- 1999-08-11 AU AU55546/99A patent/AU747640B2/en not_active Expired
- 1999-08-11 DE DE69937243T patent/DE69937243T2/de not_active Expired - Lifetime
- 1999-08-11 CA CA002338820A patent/CA2338820C/en not_active Expired - Lifetime
- 1999-08-11 CN CNB998118990A patent/CN1151263C/zh not_active Expired - Lifetime
- 1999-08-11 DK DK99942098T patent/DK1105507T3/da active
- 1999-08-11 ES ES99942098T patent/ES2291038T3/es not_active Expired - Lifetime
- 1999-08-11 AT AT99942098T patent/ATE374827T1/de active
- 1999-08-11 JP JP2000565148A patent/JP4562915B2/ja not_active Expired - Lifetime
- 1999-08-11 HU HU0103485A patent/HU230247B1/hu unknown
2007
- 2007-11-08 CY CY20071101438T patent/CY1106987T1/el unknown

Also Published As

Publication number	Publication date
HUP0103485A2 (hu)	2002-01-28
DE69937243D1 (de)	2007-11-15
CY1106987T1 (el)	2012-09-26
HUP0103485A3 (en)	2010-01-28
PT1105507E (pt)	2007-12-07
WO2000009714A1 (en)	2000-02-24
DK1105507T3 (da)	2007-11-05
US6210924B1 (en)	2001-04-03
CN1151263C (zh)	2004-05-26
AU5554699A (en)	2000-03-06
JP4562915B2 (ja)	2010-10-13
DE69937243T2 (de)	2008-07-03
WO2000009714A9 (en)	2000-05-18
AU747640B2 (en)	2002-05-16
KR20020013462A (ko)	2002-02-20
ES2291038T3 (es)	2008-02-16
CA2338820C (en)	2005-10-18
KR100502701B1 (ko)	2005-07-22
HU230247B1 (hu)	2015-11-30
CN1322253A (zh)	2001-11-14
JP2003524378A (ja)	2003-08-19
CA2338820A1 (en)	2000-02-24
EP1105507B1 (de)	2007-10-03
EP1105507A1 (de)	2001-06-13

Legal Events

Date

Code

Title

Description

2008-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1105507

Country of ref document: EP

Publication	Publication Date	Title
ATE374827T1 (de)	2007-10-15	Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1
DE3851613D1 (de)	1994-10-27	Co-Expression in eukaryontischen Zellen.
WO2000027994A3 (en)	2000-11-23	Chlamydia pneumoniae genome sequence
ATE414782T1 (de)	2008-12-15	Verfahren zur herstellung von polypeptiden in mutierten aspergillus zellen
TW200516144A (en)	2005-05-16	Novel bone mineralization proteins, DNA, vectors, expression systems
HUP9901482A2 (hu)	1999-07-28	Mesterséges kromoszómák, valamint a mesterséges kromoszómák készítése és alkalmazása
BR8200191A (pt)	1982-11-09	Celula viva renina preprorrenina prorrenina processo para obter expressao de preporrenina prorrenina e renina gene de prorrenina preprorrenina e renina e coli material dna recombinador saccharomyces cerevisiae polipetidio processo para exprimir um gene
WO2002092764A3 (en)	2003-12-24	Transgenic animal model of bone mass modulation
DE69920747D1 (de)	2004-11-04	Methode zur herstellung von rekombinanten zellen
WO1997045541A3 (en)	1998-03-26	Patched genes and their uses
DE60027570D1 (de)	2006-06-01	Verfahren zur herstellung künstlicher pflanzenchromosomen
ATE395424T1 (de)	2008-05-15	Verfahren zur herstellung von heterologen polypeptiden in trichothecene mangelmutanten filamentlösen pilzen
PT1025245E (pt)	2006-08-31	Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
Dubocanin et al.	2022	Single-molecule architecture and heterogeneity of human telomeric DNA and chromatin
ATE310085T1 (de)	2005-12-15	Cyclin-e2 proteine und dafür kodierende gene
EP0802258A3 (de)	1998-04-01	Verfahren zur Herstellung von Polydesoxyribonukleotiden, Verfahren zur Herstellung von chromosomalen DNS und Verfahren zur Herstellung von Chromosomen
GB2322132B (en)	1999-09-22	Keratinocyte growth factor-2 products
Shiokawa et al.	2002	A developmental biological study of aldolase gene expression in Xenopus laevis
Forrest et al.	1978	Tyrosyltubulin ligase and colchicine binding activity in synchronized Chinese hamster cells.
ATE358721T1 (de)	2007-04-15	Cng3b: neuartiger, zyklischer nukleotid- abhängiger kationenkanal
DE69941789D1 (de)	2010-01-21	In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten
MXPA02004825A (es)	2004-08-12	Genes especificamente expresados en celulas dendriticas humanas.
CO4790179A1 (es)	1999-05-31	Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
JP2000004715A5 (de)	2004-08-05
ATE264387T1 (de)	2004-04-15	Verfahren zur auslösung von apoptose in zellen